Kathleen Moore, MD, discusses the safety and efficacy profile of niraparib, based on data from the phase 3 trials, PRIMA; ENGOT-OV16/NOVA, and NORA.
Kathleen Moore, MD, director of the Oklahoma TSET Phase 1 Program and associate professor in the section of gynecologic oncology at the College of Medicine at the University of Oklahoma, discusses the safety and efficacy profile of niraparib (Zejula), based on data from the phase 3 trials, PRIMA; (NCT02655016), ENGOT-OV16/NOVA (NOVA; NCT01847274), and NORA (NCT03705156), which were presented during the American Society of Clinical Oncology (ASCO) Annual Meeting 2021.
According to Moore, the key takeaway is that there is not much of a difference in the safety profile of niraparib if it is used in the first-line setting versus the second-line setting. As with most PARP inhibitors, the most common adverse events (AEs) are hematologic and gastrointestinal. Thrombocytopenia was the most common hematologic AE, though it declined with individualized dosing. Grade 3 or higher anemia occurred in approximately 25% of patients. Fatigue and nausea were also observed in patients treated with niraparib during the study.
However, according to Moore, through preventative medications and setting certain expectations for patients, these AEs tend to be controllable. Efficacy was also consistent across the studies, especially in patients with BRCA-mutated ovarian cancer.
Imlunestrant Improves PFS in ESR1-Mutant Advanced Breast Cancer
December 13th 2024The phase 3 EMBER-3 trial showed imlunestrant improved PFS over SOC endocrine therapy in ER-positive, HER2-negative advanced breast cancer with ESR1 mutations, though not significantly in the overall population.
Read More
ctDNA Detection Tied to Tumor Burden, Recurrence in HR+ Early Breast Cancer
December 13th 2024A phase 2 trial showed ctDNA detection in HR-positive early breast cancer was linked to larger tumors, higher residual cancer burden, and increased recurrence after neoadjuvant endocrine therapy.
Read More
Postoperative Radiation Improves HRQOL Over Endocrine Therapy in Breast Cancer
December 13th 2024In the phase 3 EUROPA trial, exclusive postoperative radiation therapy led to better health-related quality of life and fewer treatment-related adverse events in older patients with stage I luminal-like breast cancer at 24 months.
Read More